Introduction
The proportion of patients with all types of epilepsy that are pharmacoresistant varies from study to study but can be roughly estimated to be around 30%. [1] [2] [3] This percentage will vary depending on the age of the cohort, proportion of each seizure type and different treatments given. Many studies have attempted to define the factors that could be responsible for refractory epilepsy. Some of the identified factors include response to the first treatment, 4 ,5 age at seizure onset, 6, 7 presence of generalized tonic clonic seizures (GTCS), 8 types of seizures or epilepsy 2, 6, 7 and a large number of pre-treatment seizures. 1, 7 These studies have used a wide range of diagnostic criteria as well as variable therapies. And most of them have actually focused on factors predicting a lack of long-term remission. 6, 9 Childhood absence epilepsy (CAE) is one of the most common forms of epilepsy in young children. It accounts for 10-15% of all childhood epilepsies. 10 A peak in incidence can be observed in children that are 5-7 years old 11 and it is slightly more common in girls than boys. 11, 12 CAE is characterised by absence seizures (AS) that are brief, with no post-ictal phase and occur many times a day. These can also be accompanied by GTCS or myoclonic seizures. 11, 13 All idiopathic absence epilepsies are due to a disruption of thalamo-cortical networks. The 3 Hz spike and wave discharges have been shown by Steriade and collaborators as originating from sleep oscillation generators. 14, 15 Therefore one would predict that since absence epilepsy is a well-defined clinical and pathophysiological entity, a single drug should be effective for all children with CAE. Valproic acid (VPA) is often considered to be the drug of choice for the treatment of CAE 16, 17 even though it is still unclear if it is more effective than ethosuximide (ESM) or lamotrigine (LTG). 18 Population based studies have shown that VPA can control AS in about 75% of children with CAE. 12 The remaining 25% continue to have seizures on VPA or experience side effects limiting its utilisation. In our study, we wanted to identify factors that would predict not only long-term outcome but also the initial VPA Aims: Valproic acid (VPA) is reported to be effective for the control of absence seizures in 75% of children. The aim of this study was to determine the clinical and socio-demographic factors associated with VPA response in newly diagnosed childhood absence epilepsy (CAE) and to determine if these factors also influence the chances of achieving long-term seizure freedom. response to assess its value as a predictor for the lack of long-term remission. 19 The aim of this study was to determine the clinical and sociodemographic factors associated with VPA response in children newly diagnosed with CAE and to determine if these factors also influence the chances of achieving long-term seizure freedom.
Patients and methods

Patients
The CHU Sainte Justine (Université de Montré al, Canada) offers tertiary care and specialized clinics for patients with newly diagnosed and refractory epilepsy from the greater Montreal area as well as from remote areas in the province of Quebec. All patients are referred to the neurologist by pediatric and ER doctors as well as general practitioners. They are first seen during the new diagnosis clinic and then followed during regular clinic periods for treatment and follow-up. Patients younger than 18 years old at time of diagnosis of idiopathic CAE and treated at the CHU Sainte Justine between 2000 and 2008 were retrospectively identified. Potential candidates were identified by EEG and chart review. All patients that met the diagnosis criteria of CAE (according to the ILAE 20 ) and that had been treated with VPA (Epival 1 , Depacon 1 , Depakene 1 or Depakote 1 ) were included in the study. The standard protocol for VPA treatment at the CHU Sainte Justine consists of an initial dose of 30 mg/kg/day that can be titrated up to 60 mg/kg/day depending on the patient's response, tolerance and plasma levels. EEGs with hyperventilation are performed periodically for all patients. We excluded all patients who had known brain lesions. Developmental delay and attention deficit disorder were the only two accepted neurological comorbidities. One hundred and eighty children met our study criteria and were therefore included in our sample. Medical charts of these patients were reviewed in order to determine their responsiveness to VPA and to identify clinical factors potentially related to its response.
Methods
Clinical and socio-demographical information were extracted by chart review. Variables included sex, all prenatal complications, perinatal history (including prematurity), febrile seizures, family history of epilepsy, age at AS onset, age at treatment onset, seizure frequency prior and after treatment onset, VPA efficacy and serum concentration, other AEDs used as well as other medications not related to epilepsy, coexisting seizure types (GTC or myoclonic seizures), presence of a learning disability, and finally the presence or absence of a long-term seizure freedom. The initial EEGs were only used to confirm the clinical diagnosis and were not used as a variable in the prediction of outcome.
Definitions
Seizure frequency was the average number of seizures per day prior to treatment and following the treatment as defined by the parents. It was categorized as less than 10 seizures per day and 10 or more per day. Response to treatment was considered to be a complete disappearance of AS during VPA treatment. A normal EEG during VPA treatment was also a sine qua non criterion for response. A patient was considered to be refractory to VPA if he/she continued to experience absence seizures despite a therapeutic VPA level. A patient was considered seizure free if the parents did not report any seizures, no seizures were apparent during hyperventilation and the EEG was normal. We then divided this group into two categories which were seizure free without medication and seizure free but still on medication. The latter corresponded to patients who were seizure free but the neurologist decided to pursue the treatment for more than 2 years after the last seizure to better the chances of remission.
Statistical methods
Data processing and analysis were performed with SPSS Version 14.0 (SPSS Inc., Chicago, IL, U.S.A.). Statistical comparisons between responders and non-responders used either Fisher's exact tests, x 2 tests or t-tests for independent samples. Variables associated with responsiveness (p < 0.20) in bivariate analyses were entered in a multivariable logistic regression model. This model was reduced using a backward elimination procedure (a = 0.05). Odds ratios (OR) and 95% confidence intervals (CI) were calculated. The same type of analyses was conducted using long-term seizure freedom as the dependent variable. This time, response to VPA was considered among the potential predictors. This study was approved by the Research Ethical Committees of both CHU Sainte Justine and CHU Sherbrooke.
Results
Study sample
One hundred and eighty patients identified as having CAE and treated with VPA were included in this study. The mean age at diagnosis was 7 AE 2.94 years (range 9 months-14 years 8 months) and 77 (42.8%) were male. Thirty-eight patients (21.1%) presented a single GTCS, 9 (5%) presented a single myoclonic seizure and one patient presented both. These other seizure types happened either during treatment with VPA or following treatment withdrawal. One hundred and sixty-three patients (90.6%) were given VPA as a first line treatment. The remaining 17 (9.4%) were first treated with ESM and then switched to VPA for lack of efficacy.
We had originally identified a total of 332 patients with suspected absence seizures but we had to exclude 152 patients for the following reasons: 12 presented brain lesions, 30 did not have enough information in the files, 12 had CAE but treated with a different AED, one had CAE and was prescribed VPA but the parents refused to give the treatment to their child and finally 97 were treated with VPA but had a different diagnosis than CAE.
VPA efficacy
Treatment with VPA led to seizure freedom in 112 (58.3%) patients. As shown in Table 1 , more patients refractory to VPA experienced GTCS compared to responders and had a pretreatment seizure frequency greater than 10/day (with p 0.001 in both cases). Age was also a factor significantly linked to response with patients in the responsive group being on average 16 months older at time of seizure onset, diagnosis and treatment onset (data shown in Table 2 ). However, the age at which the patients experienced their GTCS did not impact on the response to VPA.
When all factors were combined in a multivariable logistic regression analysis, we could not keep all time factors in the equation because of co-linearity. We therefore chose to keep age at diagnosis as the only time variable since age at seizure onset is known to be less reliable since it is reported by the parents and absences seizures can take some time to be recognized. In the final model shown in Table 3 , all variables that were significantly correlated to VPA response at the 5% level in the univariate analyses continued to be significant in presence of each other. A high seizure frequency (!10/day) prior to treatment and the presence of GTCS were both factors that increased the risk of nonresponse to VPA with odds ratios of 3.1 and 4.1, respectively. A higher age at diagnosis was a protective factor since it decreased the risk of non-response with an odds ratio of 0.82 which is below 1. Gender did not affect VPA response rates. The maximum VPA dosage as well as blood levels also did not correlate with response to VPA or seizure freedom.
Long-term seizure outcome
Twenty-four patients were excluded from the analysis regarding long-term outcome since these patients were still within their two first years of treatment at the end of the study period so we cannot evaluate long-term seizure freedom for these patients. As shown in Fig. 1, 45 .2% of patients achieved seizure freedom and remained so even after treatment withdrawal (58 out of 99 in the VPA responsive group and 12 out of 57 in the non-response group; p < 0.001). Sixty-one patients were also seizure free but continued to take medication (39 out of 99 in the responsive group and 22 out of 57 in the non-responsive group). The patients who were not seizure free took significantly more AEDs and continued to show an abnormal EEG (data shown in Table 4 ). Also, they were more likely to have a history of GTCS (more than twice the percentage of responders; p = 0.003).
Thirty-five patients responded to a different AED after failing VPA. The different treatment options and the number of patients who responded to these are shown in Table 5 . Ethosuximide (ESM) was most often the first drug tried after VPA failure. It was effective as a monotherapy in 8 out of 49 patients and in an additional 10 children in polytherapy. Lamotrigine (LTG) was also tried in 44 patients with four patients responding when given as a mono- CI, confidence interval; prenatal history, problems that occurred during the pregnancy; ADD, attention deficit disorder; family history of epilepsy, diagnosis of epilepsy in a first or second degree relative; ADHD, attention deficit disorder with hyperactivity; VPA, valproic acid and GTCS, generalized tonic clonic seizures. therapy and 13 in polytherapy. When both drugs were combined, five patients became seizure free. The remaining 33 patients did not respond to any of the drugs tried over the study period.
Discussion
The main finding in this study is that VPA response is associated with long-term seizure freedom in our cohort of children with CAE since 98.0% of responders were seizure free at the end of our study period. In contrast, the patients who did not respond to VPA treatment have a less favourable long-term outcome since more than a third (39.3%) of these patients do not achieve good seizure control with any AED treatment (p < 0.001).
Clinical factors predictive of VPA response
The main goal of our study was to define the clinical variables that could help us predict VPA efficacy in children with absence seizures. Our sample resembles that of other hospital-based studies even though our percentage of non-responders is in the upper range of the previously reported response rates (32.2% compared to 25-37%). 1, 5, 8, 21 Factors predicting a poor response to VPA in our study (Table 3) are in accordance with previous reports on the prognosis of CAE. 5, 11 The occurrence of GTCS is known to worsen the prognosis of children presenting with absence seizures. 8, 11 A younger age at seizure onset has also been associated with poor response to AED treatment. 7, 8 Age at seizure onset was not found to be linked to response to first AED in one study on absence seizures, 5 but that study included either treatment with VPA, ethosuximude (ESM) or carbamazepine (CBZ). We believe that including three different treatments modified the effect of certain variables, which could be predictive of response to one drug but not to another. A large number of pre-treatment seizures has already been associated with a poor response to AEDs. 1, 21 We chose to evaluate the effect of frequency of using a categorical model (more or less than 10 per day) instead of a linear model since absence seizures occur several times a day and it is hard to determine exactly when the seizures began, especially in a retrospective study. This method has also been previously used and has shown to be associated with a poor prognosis. 6 Finally, age at diagnosis was also predictive with patients responding to VPA treatment being on average 17.3 months older than the nonresponsive patients at the time of diagnosis and 14.6 months older at the occurrence of the first seizure. This is in accordance with previous studies including one, which had responders that were 17 months older at seizure onset than non-responders. 4 We chose here to take age at diagnosis instead of age at seizure onset as a predictor variable because it is a more reliable value.
Clinical factors predictive of seizure freedom
Factors linked to long-term seizure freedom are the absence of GTCS, response to VPA treatment and a low number of different AEDs taken. We do realize that these factors are not readily available at the first visit. But as clinicians we can use these factors to council parents about long-term outcome and improve treatment observance.
We could not use the standard definitions for remission (2 year or 5 year terminal remission) because this is a retrospective study and once the patients were off their medication for a certain time they did not come back to the epilepsy clinic unless they experienced a recurrence. This is the reason why we identified the group only as being seizure free for more than 2 years.
Failure of the first AED is often considered to be a poor prognosis for complete seizure control for pediatric partial epilepsy 4, 22 as well as for CAE. 5, 22 In our cohort, 90.6% were given VPA as a first line treatment and response to VPA was also strongly correlated with seizure freedom with 98.0% of children responding to VPA being seizure free at the end of the study. In contrast, non-responders have a less favorable long-term outcome. In the 17 patients that were given ESM as the first line treatment and were switched to VPA due to lack of efficacy, 11 responded to VPA and achieved seizure freedom. Four out of the six patients refractory to VPA as well, were still able to achieve seizure freedom with another AED. The poor outcome of non-responders to initial treatment might be another clinical example that seizures beget seizures. 23 But we cannot rule out that children, who do not respond to VPA, could also have a different form of epilepsy. For example it is known that frontal lobe epilepsy can mimic absence seizures and have a different outcome. 24 We therefore intend to study the genetic background of this cohort to search for seizure susceptibility genes as well as genes implicated in pharmacoresistance. In summary, the main difference in our study, compared to those looking at drug responsiveness, is that we chose to look at the clinical outcome in a group of patients with a homogeneous disorder (i.e. CAE) and a single treatment. A number of studies included patients with all types of epilepsies and then subdivided them into each category, 3, 7, 21 which diminishes the power of the statistical analysis. As our maximum age at follow-up was 18 years old, one might argue that this might be insufficient to assess complete remission because it is well known that AS can still remit at a later age. 11 However, the primary purpose of this study was to evaluate the initial response to VPA. In addition, our study suffers from certain biases and limits. First, it is a hospital-based study including patients followed in a specialized epilepsy clinic and therefore a selection bias toward refractory patients is expected. Some patients with CAE might not come to our center or are seen in the new diagnosis clinic but then followed by their pediatrician or family doctor, so seizure and epilepsy outcome were not available. The latter explanation was observed in 20 patients that were excluded. If we hypothesize that these patients were all well controlled on VPA, it could have increased our responder rate from 62.20% to 66.0%. We do realize that this calculation is highly speculative but it is only to illustrate the impact of the choice of the epilepsy clinic for the study. This bias therefore limits the generalization of our results to the general population or children with CAE. Also, we did not take into consideration race and ethnicity data because these data are not readily available in the patient's files. It would have been interesting to have this information since it is known that race and ethnicity can have an impact on response and adverse effects to certain drugs. 25 Also, one of our four predictors of poor response to VPA is the pretreatment seizure frequency. This can be misleading since it is a variable that cannot be precisely measured retrospectively. But we believe that the amounts of seizures that are missed are low in proportion to the number of seizures that are reported. Thus, by categorizing the variable, we can speculate that the underestimation can be considered equal in both groups (low and high seizures frequency). Finally, it is possible that our sample was not homogeneous because some of the patients might have been miss diagnosed as having CAE but in fact had JAE or CAE leading to JME witch might have a distinct profile and are known to be more severe cases of epilepsy than simple CAE.
Conclusion
In conclusion, we found that the factors predicting resistance to VPA were a younger age at time of diagnosis, a higher seizure frequency prior to treatment and the presence of GTC seizures. We now need to determine if these children have a different genetic profile than responders, as this might help us guide treatment and improve long-term outcome.
